KDIGO recommends SGLT2 inhibitors for patients with lower-level albuminuria (ACR < 200 mg/g) and CKD eGFR 20–45 mL/min/1.73 m2, with a slightly weaker recommendation (Class IIa/B) because of limited trial evidence but possible benefit. This evidence concerns the gene SLC5A2 and chronic kidney disease.